Supernus Pharma (SUPN) Reports Q4 Revenue of $155M
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Needham Starts NeoVolta (NEOV) at Buy
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Supernus Announces Preliminary Fourth Quarter and Full Year 2021 Financial Results
February 28, 2022 4:06 PM ESTPreliminary full year 2021 total revenues were $579.8 million; an 11% increase compared to $520.4 million in 2020SPN-830 (apomorphine infusion device) NDA accepted for review by FDA; PDUFA date early October 2022Completed acquisition of Adamas Pharmaceuticals, Inc. in November 2021; integration well underwayQelbree® continued its growth trajectory, closing the year with 13,380 prescriptions in December 2021
ROCKVILLE, Md., Feb. 28, 2022 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the... More
